Fractalkine promotes human monocyte survival via a reduction in oxidative stress.

PubWeight™: 0.85‹?›

🔗 View Article (PMC 4236230)

Published in Arterioscler Thromb Vasc Biol on October 30, 2014

Authors

Gemma E White1, Eileen McNeill1, Keith M Channon1, David R Greaves2

Author Affiliations

1: From the Sir William Dunn School of Pathology (G.E.W., D.R.G.), Division of Cardiovascular Medicine, British Heart Foundation Centre of Research Excellence, John Radcliffe Hospital (E.M., K.M.C.), and Wellcome Trust Centre for Human Genetics (E.M., K.M.C.), University of Oxford, Oxford, United Kingdom.
2: From the Sir William Dunn School of Pathology (G.E.W., D.R.G.), Division of Cardiovascular Medicine, British Heart Foundation Centre of Research Excellence, John Radcliffe Hospital (E.M., K.M.C.), and Wellcome Trust Centre for Human Genetics (E.M., K.M.C.), University of Oxford, Oxford, United Kingdom. david.greaves@path.ox.ac.uk.

Articles cited by this

Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity (2003) 21.56

Development of monocytes, macrophages, and dendritic cells. Science (2010) 12.86

Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell (1993) 10.83

Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science (2007) 9.54

Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest (2007) 8.65

A new class of membrane-bound chemokine with a CX3C motif. Nature (1997) 7.87

Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell (1997) 6.70

Nomenclature of monocytes and dendritic cells in blood. Blood (2010) 6.63

The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat Cell Biol (2003) 6.34

Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity (2012) 6.18

Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science (1993) 4.53

Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation (2008) 3.69

Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation (2003) 3.55

The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood (2003) 3.51

A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol (2000) 3.44

Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc Natl Acad Sci U S A (2006) 3.38

Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest (2003) 3.19

Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem (2001) 2.91

Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood (2001) 2.87

VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release. J Cell Biol (2001) 2.80

Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood (2011) 2.74

CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood (2008) 2.52

Beyond oxidative stress: an immunologist's guide to reactive oxygen species. Nat Rev Immunol (2013) 2.31

Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest (2003) 2.27

Differential regulation of human monocyte programmed cell death (apoptosis) by chemotactic factors and pro-inflammatory cytokines. J Immunol (1991) 2.23

Mechanisms and consequences of macrophage apoptosis in atherosclerosis. J Lipid Res (2008) 2.15

International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev (2013) 2.11

CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung. Nat Med (2010) 2.07

Posttranslational modification of Bcl-2 facilitates its proteasome-dependent degradation: molecular characterization of the involved signaling pathway. Mol Cell Biol (2000) 2.07

The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J (2006) 2.04

Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation (2000) 2.01

Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. Proc Natl Acad Sci U S A (2004) 2.00

Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1. J Biol Chem (1997) 1.93

NRROS negatively regulates reactive oxygen species during host defence and autoimmunity. Nature (2014) 1.88

Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. J Biol Chem (1998) 1.64

In vivo structure/function and expression analysis of the CX3C chemokine fractalkine. Blood (2011) 1.63

Mechanisms of ER stress-induced apoptosis in atherosclerosis. Arterioscler Thromb Vasc Biol (2011) 1.60

The fractalkine receptor CX₃CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. Hepatology (2010) 1.59

The chemokine fractalkine inhibits Fas-mediated cell death of brain microglia. J Immunol (2000) 1.53

Fas mediates apoptosis in human monocytes by a reactive oxygen intermediate dependent pathway. J Immunol (1996) 1.51

The transmembrane form of the CX3CL1 chemokine fractalkine is expressed predominantly by epithelial cells in vivo. Am J Pathol (2001) 1.49

Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation (2003) 1.40

Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity. J Immunol (2002) 1.23

Bcl-2 family proteins as regulators of oxidative stress. Semin Cancer Biol (2008) 1.23

Enhanced adhesive capacities of the naturally occurring Ile249-Met280 variant of the chemokine receptor CX3CR1. J Biol Chem (2004) 1.15

Chemokines in atherosclerosis: proceedings resumed. Arterioscler Thromb Vasc Biol (2014) 1.13

Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling. Cardiovasc Res (2009) 1.11

The role of fractalkine in the recruitment of monocytes to the endothelium. Eur J Pharmacol (2000) 1.11

Fractalkine, a CX3C-chemokine, functions predominantly as an adhesion molecule in monocytic cell line THP-1. Immunol Cell Biol (2001) 1.06

Neuronal expression of fractalkine in the presence and absence of inflammation. FEBS Lett (1998) 1.03

Reduced inflammatory and neuropathic pain and decreased spinal microglial response in fractalkine receptor (CX3CR1) knockout mice. J Neurochem (2010) 1.03

Association of leukocyte subtype counts with coronary atherosclerotic regression following pravastatin treatment. Am J Cardiol (2009) 1.00

Pharmacological inhibition of the chemokine receptor, CX3CR1, reduces atherosclerosis in mice. Arterioscler Thromb Vasc Biol (2013) 0.97

Genetic diversity of CX3CR1 gene and coronary artery disease: new insights through a meta-analysis. Atherosclerosis (2009) 0.96

Adverse associations between CX3CR1 polymorphisms and risk of cardiovascular or cerebrovascular disease. Arterioscler Thromb Vasc Biol (2005) 0.96

Impact of leukocyte count on mortality and bleeding in patients with myocardial infarction undergoing primary percutaneous coronary interventions: analysis from the Harmonizing Outcome with Revascularization and Stent in Acute Myocardial Infarction trial. Circulation (2011) 0.88

Substituted 7-amino-5-thio-thiazolo[4,5-d]pyrimidines as potent and selective antagonists of the fractalkine receptor (CX3CR1). J Med Chem (2013) 0.85

Monocytes expressing CX3CR1 orchestrate the development of vincristine-induced pain. J Clin Invest (2014) 0.85

The CD14(+/low)CD16(+) monocyte subset is more susceptible to spontaneous and oxidant-induced apoptosis than the CD14(+)CD16(-) subset. Cell Death Dis (2010) 0.83

Proline 326 in the C terminus of murine CX3CR1 prevents G-protein and phosphatidylinositol 3-kinase-dependent stimulation of Akt and extracellular signal-regulated kinase in Chinese hamster ovary cells. J Pharmacol Exp Ther (2005) 0.82

Pathological role of fractalkine/CX3CL1 in rheumatic diseases: a unique chemokine with multiple functions. Front Immunol (2012) 0.81

Site-directed mutagenesis of the chemokine receptor CXCR6 suggests a novel paradigm for interactions with the ligand CXCL16. Eur J Immunol (2008) 0.79